Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioCorRx Inc. (BICX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.1000-0.3600 (-8.07%)
At close: 01:43PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.4600
Open4.4800
BidN/A x N/A
AskN/A x N/A
Day's Range4.1000 - 4.4800
52 Week Range1.0100 - 8.1000
Volume6,893
Avg. Volume2,593
Market Cap27.432M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.7950
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference

    ANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., and Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

  • GlobeNewswire

    BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board

    ANAHEIM, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory Board (SAB). Dr. Jie Shen is an Assistant Professor in the Departments of Biomedical and Pharmaceutical Sciences and Chemical Engineering at the University of Rhode Island (URI). Prior to joining URI, Dr. Shen wa

  • GlobeNewswire

    BioCorRx to Participate in the Benzinga All Access Event on December 2nd

    ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will be participating in the Benzinga All Access event taking place on December 2, 2021. Ms. Felix and Mr. Granier are scheduled to pre

Advertisement
Advertisement